The University of Southampton
University of Southampton Institutional Repository

Evaluating the cost implications of integrating SARS-CoV-2 genome sequencing for infection prevention and control investigation of nosocomial transmission within hospitals

Evaluating the cost implications of integrating SARS-CoV-2 genome sequencing for infection prevention and control investigation of nosocomial transmission within hospitals
Evaluating the cost implications of integrating SARS-CoV-2 genome sequencing for infection prevention and control investigation of nosocomial transmission within hospitals

BACKGROUND: The COG-UK hospital-onset COVID-19 infection (HOCI) trial evaluated the impact of SARS-CoV-2 whole-genome sequencing (WGS) on acute infection, prevention, and control (IPC) investigation of nosocomial transmission within hospitals.

AIM: To estimate the cost implications of using the information from the sequencing reporting tool (SRT), used to determine likelihood of nosocomial infection in IPC practice.

METHODS: A micro-costing approach for SARS-CoV-2 WGS was conducted. Data on IPC management resource use and costs were collected from interviews with IPC teams from 14 participating sites and used to assign cost estimates for IPC activities as collected in the trial. Activities included IPC-specific actions following a suspicion of healthcare-associated infection (HAI) or outbreak, as well as changes to practice following the return of data via SRT.

FINDINGS: The mean per-sample costs of SARS-CoV-2 sequencing were estimated at £77.10 for rapid and £66.94 for longer turnaround phases. Over the three-month interventional phases, the total management costs of IPC-defined HAIs and outbreak events across the sites were estimated at £225,070 and £416,447, respectively. The main cost drivers were bed-days lost due to ward closures because of outbreaks, followed by outbreak meetings and bed-days lost due to cohorting contacts. Actioning SRTs, the cost of HAIs increased by £5,178 due to unidentified cases and the cost of outbreaks decreased by £11,246 as SRTs excluded hospital outbreaks.

CONCLUSION: Although SARS-CoV-2 WGS adds to the total IPC management cost, additional information provided could balance out the additional cost, depending on identified design improvements and effective deployment.

COVID-19, Cost, Healthcare-associated infection, Infection prevention and control, Micro-costing, SARS-CoV-2
0195-6701
23-32
Panca, M
9d56e984-1b81-4ed7-b9e1-2518ed59836b
Blackstone, J
c2d01b3d-0227-47f3-a384-5d250124cf47
Stirrup, O
ae9630c0-36c0-4a35-93c1-19bbe3c9ef85
Cutino-Moguel, M-T
5d3e06c8-1bdd-4806-9415-05e87596bb23
Thomson, E
56756701-c8db-4b95-a453-910601c1f096
Peters, C
2f400730-39ef-45f9-bb77-434d806361b5
Snell, L B
2cd1a0a9-475e-4240-bc2c-aacd0e0cd749
Nebbia, G
3265d964-9d7b-4424-b698-c30a35175c00
Holmes, A
d8f41df7-f2a0-45e5-a869-68b7bc76dde3
Chawla, A
a7528db3-560b-4688-ad38-cbf077bfffb7
Machin, N
f1f35bfc-f2c2-4ea7-8360-26684f564f8c
Taha, Y
e7fc4688-2881-4f0a-915b-9657a5e288f3
Mahungu, T
317f36a9-c0c9-4e8d-a25f-8fe2cbc7083f
Saluja, T
1c9a4f8e-f8b5-4020-95ac-b59822960759
de Silva, T I
12f6f062-7a97-408f-9f66-5bc5fe15ba4c
Saeed, Kordo
87cb67e5-71e8-4759-bf23-2ea00ebd8b39
Pope, C
21ae1290-0838-4245-adcf-6f901a0d4607
Shin, G Y
d8394a15-47ef-41cf-ab91-6d95f3313bd6
Williams, R
ee44382b-3c7c-4e39-8418-5c96483dbaf8
Darby, A
40e52ac7-914f-4fbc-b5d1-29912b81573b
Smith, D L
53034967-7cda-427d-ac20-8c857fe3eb26
Loose, M
f79e2b90-8494-4b48-af76-0932d0c41079
Robson, S C
dc9d843b-2cff-44b6-9706-479001c5a030
Laing, K
5027753e-c0ef-42d4-9e9b-2b3506f1d466
Partridge, D G
5ef69aca-58ec-4e36-815b-d301ff7845e5
Price, J R
92ef44f2-70b4-410f-8498-2846b0f00ae2
Breuer, J
2c93e1ce-4a71-4ca6-8e9a-031e76e55bb4
Panca, M
9d56e984-1b81-4ed7-b9e1-2518ed59836b
Blackstone, J
c2d01b3d-0227-47f3-a384-5d250124cf47
Stirrup, O
ae9630c0-36c0-4a35-93c1-19bbe3c9ef85
Cutino-Moguel, M-T
5d3e06c8-1bdd-4806-9415-05e87596bb23
Thomson, E
56756701-c8db-4b95-a453-910601c1f096
Peters, C
2f400730-39ef-45f9-bb77-434d806361b5
Snell, L B
2cd1a0a9-475e-4240-bc2c-aacd0e0cd749
Nebbia, G
3265d964-9d7b-4424-b698-c30a35175c00
Holmes, A
d8f41df7-f2a0-45e5-a869-68b7bc76dde3
Chawla, A
a7528db3-560b-4688-ad38-cbf077bfffb7
Machin, N
f1f35bfc-f2c2-4ea7-8360-26684f564f8c
Taha, Y
e7fc4688-2881-4f0a-915b-9657a5e288f3
Mahungu, T
317f36a9-c0c9-4e8d-a25f-8fe2cbc7083f
Saluja, T
1c9a4f8e-f8b5-4020-95ac-b59822960759
de Silva, T I
12f6f062-7a97-408f-9f66-5bc5fe15ba4c
Saeed, Kordo
87cb67e5-71e8-4759-bf23-2ea00ebd8b39
Pope, C
21ae1290-0838-4245-adcf-6f901a0d4607
Shin, G Y
d8394a15-47ef-41cf-ab91-6d95f3313bd6
Williams, R
ee44382b-3c7c-4e39-8418-5c96483dbaf8
Darby, A
40e52ac7-914f-4fbc-b5d1-29912b81573b
Smith, D L
53034967-7cda-427d-ac20-8c857fe3eb26
Loose, M
f79e2b90-8494-4b48-af76-0932d0c41079
Robson, S C
dc9d843b-2cff-44b6-9706-479001c5a030
Laing, K
5027753e-c0ef-42d4-9e9b-2b3506f1d466
Partridge, D G
5ef69aca-58ec-4e36-815b-d301ff7845e5
Price, J R
92ef44f2-70b4-410f-8498-2846b0f00ae2
Breuer, J
2c93e1ce-4a71-4ca6-8e9a-031e76e55bb4

Panca, M, Blackstone, J, Stirrup, O, Cutino-Moguel, M-T, Thomson, E, Peters, C, Snell, L B, Nebbia, G, Holmes, A, Chawla, A, Machin, N, Taha, Y, Mahungu, T, Saluja, T, de Silva, T I, Saeed, Kordo, Pope, C, Shin, G Y, Williams, R, Darby, A, Smith, D L, Loose, M, Robson, S C, Laing, K, Partridge, D G, Price, J R and Breuer, J (2023) Evaluating the cost implications of integrating SARS-CoV-2 genome sequencing for infection prevention and control investigation of nosocomial transmission within hospitals. The Journal of hospital infection, 139, 23-32. (doi:10.1016/j.jhin.2023.06.005).

Record type: Article

Abstract

BACKGROUND: The COG-UK hospital-onset COVID-19 infection (HOCI) trial evaluated the impact of SARS-CoV-2 whole-genome sequencing (WGS) on acute infection, prevention, and control (IPC) investigation of nosocomial transmission within hospitals.

AIM: To estimate the cost implications of using the information from the sequencing reporting tool (SRT), used to determine likelihood of nosocomial infection in IPC practice.

METHODS: A micro-costing approach for SARS-CoV-2 WGS was conducted. Data on IPC management resource use and costs were collected from interviews with IPC teams from 14 participating sites and used to assign cost estimates for IPC activities as collected in the trial. Activities included IPC-specific actions following a suspicion of healthcare-associated infection (HAI) or outbreak, as well as changes to practice following the return of data via SRT.

FINDINGS: The mean per-sample costs of SARS-CoV-2 sequencing were estimated at £77.10 for rapid and £66.94 for longer turnaround phases. Over the three-month interventional phases, the total management costs of IPC-defined HAIs and outbreak events across the sites were estimated at £225,070 and £416,447, respectively. The main cost drivers were bed-days lost due to ward closures because of outbreaks, followed by outbreak meetings and bed-days lost due to cohorting contacts. Actioning SRTs, the cost of HAIs increased by £5,178 due to unidentified cases and the cost of outbreaks decreased by £11,246 as SRTs excluded hospital outbreaks.

CONCLUSION: Although SARS-CoV-2 WGS adds to the total IPC management cost, additional information provided could balance out the additional cost, depending on identified design improvements and effective deployment.

This record has no associated files available for download.

More information

e-pub ahead of print date: 9 June 2023
Published date: September 2023
Additional Information: Funding Information: Members of different teams who provided data:, Infection Prevention and Control: M. Cummins (Barts Health NHS Trust, London, UK); G. Mollett, A. Marek (NHS Greater Glasgow and Clyde, Glasgow, UK); C. Beviz, H. Mitchell (Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK); B. Taylor, D. Lankstead (Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK); K. Wylie (Manchester University NHS Foundation Trust, Manchester, UK); A. Cobb (Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK); E. Baxter (Nottingham University Hospitals NHS Trust, Nottingham, UK); D. Thomlinson (City Hospital, Birmingham, UK); L. Hail (University College London Hospitals NHS Foundation Trust, London, UK). Income, Contracting and Costing: D. Jaramillo (Barts Health NHS Trust, London, UK); J. Haughney (NHS Greater Glasgow and Clyde, Glasgow, UK); S. Mookerjee (Imperial College Healthcare NHS Trust, London, UK); P. Dudley, C. Wilson (Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK); J. Field (Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK). Laboratories: A. Da Silva Filipe, D. Macpherson, D. Mair (NHS Greater Glasgow and Clyde, Glasgow, UK); C. McCann (Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK); J. Schutter (University of Sheffield, Sheffield, UK); K. Laing (St George's University Hospitals NHS Foundation Trust, London, UK); A. Beckett (Centre for Enzyme Innovation, University of Portsmouth, Portsmouth, UK); S. Glaysher (Portsmouth Hospitals University NHS Trust, Portsmouth, UK); K.F. Cook, C. Fearn, S. Goudarzi, H. Dent, H. Paul (School of Pharmacy and Biomedical Science & School of Biological Sciences, University of Portsmouth, Portsmouth, UK). K. Saeed would like to thank M. Connell, B. James and other colleagues in the Costing/Central Management Accounting Team at University Hospital Southampton as well as J. Brookes, S. Dailly, S. Jeremiah, J. Prieto, C. Holmes, T. Julius, A. Elliott, P. Doherty, K. Chandler, D. Court, S. Aplin and other colleagues in infection prevention at University Hospital Southampton for all their support during those challenging times and providing some of the interviews and costing calculations for the study. Funding Information: The study was funded by UK Research and Innovation and the Wellcome Trust through the COG-UK Consortium grant. J. Breuer receives funding from the National Institute for Health Research UCL/UCLH Biomedical Research Centre. Publisher Copyright: © 2023 The Authors
Keywords: COVID-19, Cost, Healthcare-associated infection, Infection prevention and control, Micro-costing, SARS-CoV-2

Identifiers

Local EPrints ID: 481110
URI: http://eprints.soton.ac.uk/id/eprint/481110
ISSN: 0195-6701
PURE UUID: f77b4a8a-1723-44b8-90c5-d6ad6835226b
ORCID for Kordo Saeed: ORCID iD orcid.org/0000-0003-0123-0302
ORCID for C Pope: ORCID iD orcid.org/0000-0002-8935-6702

Catalogue record

Date deposited: 15 Aug 2023 16:54
Last modified: 18 Mar 2024 03:52

Export record

Altmetrics

Contributors

Author: M Panca
Author: J Blackstone
Author: O Stirrup
Author: M-T Cutino-Moguel
Author: E Thomson
Author: C Peters
Author: L B Snell
Author: G Nebbia
Author: A Holmes
Author: A Chawla
Author: N Machin
Author: Y Taha
Author: T Mahungu
Author: T Saluja
Author: T I de Silva
Author: Kordo Saeed ORCID iD
Author: C Pope ORCID iD
Author: G Y Shin
Author: R Williams
Author: A Darby
Author: D L Smith
Author: M Loose
Author: S C Robson
Author: K Laing
Author: D G Partridge
Author: J R Price
Author: J Breuer

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×